CG Oncology aims for $209M IPO, as more biotechs eye path to public markets
Investment firm Mirae launches its US biotech VC fund with $50M
Return of the SPAC? Bihua Chen and Cormorant go for round two after MoonLake success
Novartis axes PhIII peanut allergy trial in another blow for once-hopeful Xolair successor
BridgeBio raises up to $1.2B, a month after submitting cardio drug to FDA
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors
Novo Holdings plans to ramp up dealmaking amid Wegovy windfall: Bloomberg
JPM24: Roche’s pharma BD chief explains renewed ADC interest but is spoilt for choice
Novartis reportedly backs out of Cytokinetics deal, denting biotech’s stock
Illumina Ventures launches refreshed genomics startup accelerator program
ArriVent outlines plans for $135M IPO in second biotech listing of 2024
Coherus sells Sandoz its Lucentis biosimilar for $170M to focus on oncology assets
Former Theranos CEO Elizabeth Holmes is banned from federal health programs for almost a century
AstraZeneca, Boehringer Ingelheim, GSK defend patent listings as Klobuchar amps up pressure